Irlande - anglais - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - enrofloxacin - infus/pdr/oral soln - 100 mg/ml - enrofloxacin - fowl - chicken, fowl - turkey - antibacterial

Irlande - anglais - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - enrofloxacin - oral solution - 100 milligram(s)/millilitre - enrofloxacin - chickens, turkeys - antibacterial

Espagne - anglais - HMA (Heads of Medicines Agencies)

universal farma s.l. - enrofloxacin 100 mg/ml - oral solution - chicken food, rabbit food - enrofloxacin

Italie - anglais - HMA (Heads of Medicines Agencies)

universal farma s.l. - enrofloxacin 100 mg/ml - oral solution - chicken food, rabbit food - enrofloxacin

Portugal - anglais - HMA (Heads of Medicines Agencies)

universal farma s.l. - enrofloxacin 100 mg/ml - oral solution - chicken food, rabbit food - enrofloxacin

États-Unis - anglais - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), silver sulfadiazine (unii: w46jy43ejr) (sulfadiazine - unii:0n7609k889) - enrofloxacin 5 mg in 1 ml - baytril® otic is indicated as a treatment for canine otitis externa complicated by bacterial and fungal organisms susceptible to enrofloxacin and/or silver sulfadiazine (see microbiology section). baytril® otic is contraindicated in dogs with suspected or known hypersensitivity to quinolones and/or sulfonamides.

États-Unis - anglais - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), butyl alcohol (unii: 8pj61p6ts3) (butyl alcohol - unii:8pj61p6ts3) - enrofloxacin 22.7 mg in 1 ml - baytril® (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. efficacy confirmation: clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of escherichia coli , klebsiella pneumoniae , proteus mirabilis , and staphylococcus intermedius ; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of escherichia coli and staphylococcus aureus ; and urinary cystitis associated with susceptible strains of escherichia coli , proteus mirabilis , and staphylococcus aureus . enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in lar

États-Unis - anglais - NLM (National Library of Medicine)

professional compounding centers of america dba pcca - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin usp for veterinary use only *protect from light* for prescription compounding/rx only part: 30-4815 gm cas: 93106-60-6 danger: harmful substance. irritating substance. may cause eye, skin or respiratory irritation. possible hypersensitization. avoid raising and breathing dust use adequate ventilation. avoid alkalies. emits toxic fumes under fire conditions. wash thoroughly after handling. store in tightly closed container. preserve in well-closed,light resistant container. store at room temperature.

Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - enrofloxacin - unknown - enrofloxacin antibiotic active 0.0 - active constituent

États-Unis - anglais - NLM (National Library of Medicine)

sparhawk laboratories, inc - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - cattle-single-dose therapy:  enrofloxacin 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis in beef and non-lactating dairy cattle; and for the control of brd in beef and non-lactating dairy cattle at high risk of developing brd associated with m. haemolytica, p. multocida, h. somni and m. bovis . cattle-multiple-day therapy:  enrofloxacin 100 is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida and histophilus somni in beef and non-lactating dairy cattle. swine:  enrofloxacin 100 is indicated for the treatment and control of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, streptococcus suis, bordetella bronchiseptica and mycoplasma hyopneumoniae.  enrofloxacin 100 is indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with escherichia coli has been diagnosed.